# GPT 5.2 Review - Reviewer 1/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-28T18:50:48.941502
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_0445c6c79cfbc72a00697a4bde1b308195a5a08b85e0c241b6
**Tokens:** 16418 in / 5676 out
**Response SHA256:** 166b7b76ed8a05de

---

## Referee Report

### Summary / contribution
The paper asks whether **Extreme Risk Protection Order (ERPO)** laws (“red flag” laws) reduce suicides. Using a **1999–2017 state-year panel** and staggered DiD (primarily **Callaway & Sant’Anna, 2021**), the authors report a **positive** estimated effect of ERPO adoption on *total* suicide rates (ATT ≈ **+0.53 per 100,000**, SE 0.19), while TWFE is negative and insignificant. The manuscript is admirably candid that inference is unreliable with only **3 treated clusters** in the main spec and that the positive estimate likely reflects **policy endogeneity / reverse causation**.

For a top general-interest journal, the current version is not close: the design has **too little identifying variation**, **no credible inference**, and the estimand (total suicides) is misaligned with the mechanism (firearm access). The paper can be salvaged only if it is reframed and re-executed around (i) **post-2018 adoption wave**, (ii) **firearm suicide outcomes**, and (iii) **valid inference under few treated clusters** and/or alternative designs (synthetic control / synthetic DiD / RI).

---

# 1. FORMAT CHECK

**Length**
- Main text appears to run roughly **pp. 1–20** (Conclusion ends around p.19–20), with **References ~pp. 21–23** and Appendix through **p. 28**.  
- Therefore **< 25 pages excluding references/appendix**, failing your stated threshold for this check (even though top journals do not literally require 25 pages, many published papers exceed it and contain substantially more analysis than here).

**References**
- Methods: cites the core staggered DiD papers (Callaway–Sant’Anna; Sun–Abraham; Goodman-Bacon; de Chaisemartin–D’Haultfoeuille; Borusyak et al.; Roth). That part is decent.
- Substantive ERPO / firearm-suicide literature is **thin** and does not engage several key empirical and measurement papers (details in Section 4 below).

**Prose vs bullets**
- Introduction and most sections are in paragraphs.
- However, **Section 6.1** (Discussion) contains a **bullet-style list** (“TWFE vs. C-S discordance”, “Outcome mismatch”, “Limited treated units”, etc.). For AER/QJE/JPE/ReStud/Ecta/AEJ:EP quality, this needs to be converted into **full prose with a coherent argumentative structure**.

**Section depth**
- Intro is sufficiently developed (multiple paragraphs).
- Institutional background and discussion are long enough, but **Results (Section 5)** reads short relative to the importance of empirics; it lacks the depth expected for a general-interest outlet (e.g., no serious alternative designs, no serious inference, no heterogeneity with meaning, no mechanisms).

**Figures**
- Figures shown have axes and visible data (e.g., event-study plot; trends; map).
- But the event-study figure (p. 13 in the excerpt) shows very wide uncertainty and volatile pre-trends; it needs redesign and clearer indication of support (which cohorts contribute to each event time).

**Tables**
- Tables contain real numbers (no placeholders). Good.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

This is where the paper fails for publication.

### (a) Standard Errors
- Main estimates (Table 3, p. 11) do report SEs in parentheses.  
- Some robustness results in Table 4 (p. 13) report ATT and SEs.  
- **But** cohort-time/event-time estimates shown in figures do not provide underlying numeric tables; this is fixable.

### (b) Significance testing
- The paper provides conventional SE-based CIs (Table 3).  
- However, the authors repeatedly note (correctly) that **conventional inference is unreliable with only 3 treated clusters** (Section 4.3; Table 3 notes; Figure notes; Section 6.3). This is not just a caveat—**it makes the results non-testable as presented**.

### (c) Confidence intervals
- Table 3 reports 95% CIs. Good.

### (d) Sample sizes
- N is reported (Table 3; Table 4). Good.

### (e) Staggered DiD
- The paper does not rely solely on TWFE; it uses **Callaway–Sant’Anna**. This is the correct direction.  
- But: with **only 3 treated states** in the main analysis (IN, CA, WA) and effectively **two informative cohorts** (IN has long post; CA has 2 post; WA has 1 post), DiD is not doing what readers expect. You are estimating something close to an “Indiana before/after vs. rest” plus a tiny “California 2016–2017 vs. rest” comparison.

### (f) Inference is the fatal flaw
A paper **cannot pass** at a top journal without credible inference. Here, inference is not credible because:
1. **Treated clusters = 3** (main) or 4 (including CT with contaminated pre). Cluster-robust asymptotics are inapplicable.
2. You do not implement a principled few-treated-cluster approach (you cite Conley–Taber but do not use it).
3. The reported SEs/CIs are therefore not interpretable for hypothesis testing, and the authors themselves say so.

**Bottom line:** as currently executed, the paper is **unpublishable** in a top outlet because it does not deliver valid inference for its central claim.

**What is required to fix this (minimum bar):**
- Implement **randomization inference / permutation inference** tailored to staggered adoption (e.g., assign placebo adoption years to control states; compute the distribution of ATT under sharp null).
- Implement **Conley & Taber (2011)** style inference (or modern extensions) for DiD with few treated groups.
- Implement **wild cluster bootstrap** with small-cluster corrections, and be explicit about what is being bootstrapped and under what assumptions.
- Show that conclusions do not hinge on one treated state (leave-one-treated-out is necessary but not sufficient; you partly do this by dropping WA, but more is needed).

---

# 3. IDENTIFICATION STRATEGY

### Credibility
Identification is not credible as stated, mainly because:
- **Policy adoption is plausibly endogenous to suicide trends** (your preferred explanation). If so, the parallel trends assumption fails in the most consequential way.
- Event studies show **volatile and non-zero pre-trends** (Figure 1; Figure 4). With few treated states, the plot is not decisive, but it is certainly not reassuring.

### Key assumptions
- Parallel trends is discussed (Section 4.1; 6.4). Good.
- But discussion does not translate into an empirically credible solution. Simply stating “reverse causation likely” is essentially an admission that the main design cannot identify a causal effect.

### Placebos / robustness
- Robustness table (Table 4) is mostly variations of the same estimator with the same weak identifying variation.
- There are no serious placebos:
  - No placebo outcomes plausibly unaffected by ERPO (e.g., cancer mortality, accidental falls, etc.).
  - No placebo adoption years (re-assign treatment to pseudo-treated states).
  - No “negative control” exposures.
- No alternative identification strategies are pursued (synthetic control / SDID / interactive fixed effects / factor models / SC with RI).

### Conclusions vs evidence
The paper’s *interpretation* (“likely reverse causation”) is plausible and cautious. But the *headline empirical result* is not supported by credible identification or inference. In a top journal, you need either:
1) a credible design that identifies causal effects, or  
2) a paper explicitly about the failure of standard designs in this setting, backed by formal diagnostics and simulation/RI evidence.  
Right now, it is halfway between the two.

---

# 4. LITERATURE (missing references + BibTeX)

### Methods literature you should engage (missing or underused)
You mention synthetic control only in the references (Abadie et al., 2010), but do not use SC/SDID—this is a major gap given your setting (few treated units).

1) **Synthetic Difference-in-Differences (SDID)**  
This is arguably the *default* modern approach when treated units are few and adoption timing is not rich.
```bibtex
@article{Arkhangelsky2021,
  author  = {Arkhangelsky, Dmitry and Athey, Susan and Hirshberg, David A. and Imbens, Guido W. and Wager, Stefan},
  title   = {Synthetic Difference-in-Differences},
  journal = {American Economic Review},
  year    = {2021},
  volume  = {111},
  number  = {12},
  pages   = {4088--4118}
}
```

2) **Augmented Synthetic Control (ASC)** (useful for bias reduction and inference)
```bibtex
@article{BenMichael2021,
  author  = {Ben-Michael, Eli and Feller, Avi and Rothstein, Jesse},
  title   = {The Augmented Synthetic Control Method},
  journal = {Journal of the American Statistical Association},
  year    = {2021},
  volume  = {116},
  number  = {536},
  pages   = {1789--1803}
}
```

3) **Few treated groups in DiD inference** (you cite Conley–Taber but should also cite and/or use complementary approaches)
```bibtex
@article{FermanPinto2019,
  author  = {Ferman, Bruno and Pinto, Cristine},
  title   = {Inference in Differences-in-Differences with Few Treated Groups and Heteroskedasticity},
  journal = {Review of Economics and Statistics},
  year    = {2019},
  volume  = {101},
  number  = {3},
  pages   = {452--467}
}
```

4) **Sensitivity to parallel trends violations** (you mention Roth (2022) but not the key “credible parallel trends” framework)
```bibtex
@article{RambachanRoth2023,
  author  = {Rambachan, Ashesh and Roth, Jonathan},
  title   = {A More Credible Approach to Parallel Trends},
  journal = {Review of Economic Studies},
  year    = {2023},
  volume  = {90},
  number  = {5},
  pages   = {2555--2591}
}
```

### Policy/substantive literature missing or insufficiently engaged
Your ERPO discussion leans heavily on Swanson et al. (2017), Kivisto et al. (2018), and RAND. That is not enough for a top field/general journal. At minimum you should incorporate:
- Work on **California GVRO implementation and outcomes** (even if focused on violence, it informs intensity/usage and timing).
- Work on **firearm suicide policy effects** in quasi-experimental designs (waiting periods, PTP laws, background checks) to benchmark magnitudes and to justify outcome choice.

For example, waiting periods and gun deaths:
```bibtex
@article{LucaMalhotraPoliquin2017,
  author  = {Luca, Michael and Malhotra, Deepak and Poliquin, Christopher},
  title   = {Handgun Waiting Periods Reduce Gun Deaths},
  journal = {Proceedings of the National Academy of Sciences},
  year    = {2017},
  volume  = {114},
  number  = {46},
  pages   = {12162--12165}
}
```
(If you want to stay strictly within econ journals, you can add complementary citations, but PNAS is widely cited in this area and acceptable in AEJ:EP/AER-style policy work.)

Also, you should cite more directly on **means restriction and substitution** beyond Barber & Miller (2008), including systematic reviews and empirical substitution work (public health / epidemiology literature is relevant here because your mechanism is clinical/behavioral).

### Positioning
The contribution is currently framed as “early adopters + modern DiD.” But early adopters provide too little variation to deliver credible inference. The paper must either:
- pivot to **post-2018 wave** (more adopters, more power, more variation), or
- pivot to **within-state utilization intensity** (county-level petitions; dosage), or
- pivot to **case-level** outcomes (ERPO recipients) combined with a credible counterfactual.

---

# 5. WRITING QUALITY (CRITICAL)

### Prose vs bullets
- Mostly strong, readable prose.
- But the Discussion (Section 6.1) partially turns into bullet-list logic. For top journals, convert these into paragraphs with explicit logical connections and explicit “therefore” structure.

### Narrative flow
- The hook is clear and policy-relevant.
- However, the narrative arc breaks when the main result is “positive but not credible.” A top-journal reader will ask: *what did we learn, causally?* Right now, the answer is: “we learned it’s hard.” That can be publishable only if the paper becomes a **methodological/policy-evaluation cautionary tale** with formal evidence (e.g., showing how estimators behave under endogenous adoption; simulations calibrated to this setting; RI showing estimates are not distinguishable from plausible placebo assignments).

### Accessibility and magnitudes
- Magnitudes are sometimes contextualized (4% of mean). Good.
- But you should translate ATT into implied numbers of deaths per year (state-population weighted), and compare with plausible ERPO reach (orders per year) to check if a detectable population effect is even feasible.

### Tables/figures quality
- Acceptable for a working paper; not yet at publication quality (fonts, clarity about support, cohort contributions, and uncertainty methods).

---

# 6. CONSTRUCTIVE SUGGESTIONS (how to make it publishable)

### A. Fix inference first (non-negotiable)
1. **Randomization inference**:  
   - Define an assignment mechanism (e.g., choose 3 states at random as “treated” with the same adoption years; or permute adoption years among states; or treat “law-on-the-books by 2017” as the assignment).  
   - Report the randomization-based p-value for your ATT and event-study path under the sharp null.
2. **Conley–Taber inference** (or Ferman–Pinto):  
   - Implement CI construction appropriate for few treated groups.
3. **Wild cluster bootstrap** with small-cluster corrections:  
   - Be explicit and transparent; show sensitivity across bootstrap variants.

### B. Change the design: early adopters are not enough
For a serious causal paper, you need more adoption variation:
- **Extend the panel to 2023/2024** and include the **2018–2020 adoption wave**. This is the single most important substantive improvement.
- Use **firearm suicide** (X72–X74), not total suicide. If API constraints exist, build a replicable pipeline:
  - Use restricted-access microdata if possible; or
  - Use WONDER downloads with scripted reproducible steps; or
  - Use NVSS multiple cause-of-death files (CDC) and compute rates yourself.

### C. Consider alternative estimators suited to few treated units
- **Synthetic control / SDID / ASC** for each early adopter, with RI-based inference.  
This is far more appropriate than hoping staggered DiD works with 3 treated states.

### D. Measure treatment intensity
Binary adoption is likely too coarse. If ERPOs are rare initially, population effects will be mechanically tiny.
- Collect annual (or county-year) **petition/order counts** and run dose-response analyses.
- If county data are feasible, you can do a within-state design around implementation surges (training, court guidance, mass-shooting salience shocks) with stronger counterfactuals.

### E. Improve causal story and falsification
- Add **negative control outcomes** and **placebo policies**.
- Add **mechanism checks**: firearm suicide vs non-firearm suicide; firearm ownership heterogeneity; baseline mental health infrastructure; contemporaneous opioid mortality.

---

# 7. OVERALL ASSESSMENT

### Strengths
- Important question, clear policy relevance.
- Uses modern staggered DiD estimators rather than naive TWFE.
- Unusually transparent about limitations and endogeneity concerns.

### Critical weaknesses
- **No credible inference** with 3 treated clusters; cluster-robust SEs are not valid here and the paper admits it.
- **Identification is not credible**: endogenous adoption is likely first-order; pre-trends are not reassuring.
- Outcome is **misaligned with mechanism** (total suicide rather than firearm suicide).
- The empirical contribution is too thin for a top journal (short post periods for CA/WA; CT pre-period contamination; minimal robustness beyond estimator toggles).

### What I would need to recommend publication
A redesigned paper with:
1) extended post-2017 data and many adopters,  
2) firearm-specific outcomes,  
3) valid few-treated-cluster inference (RI/CT/WCB), and  
4) either SDID/SC evidence or a stronger quasi-experimental source of variation (implementation intensity shocks).

---

DECISION: REJECT AND RESUBMIT